Abstract 1753P
Background
Myxofibrosarcoma (MFS) are malignant tumors usually diagnosed in the extremities or trunk of elderly patients. Prognosis in this sarcoma subtype is dismal due to high risk of local recurrence. Our aim was to analyze the treatment results of patients (pts) diagnosed with localized myxofibrosarcoma, taking into account also surgical complications.
Methods
245 pts (51% male) with locally advanced myxofibrosarcoma treated in 2015-2020 were included in this retrospective analysis. Data on tumor characteristic and long-term survival and surgical complications were collected. Kaplan-Meier estimator with log-rank test was used for survival analysis. Median follow-up was 70 months (95%CI 67.2-79.7).
Results
The mean age was 63 years. 65% of the pts had no prior treatment, and 24% were referred after non-radical excision outside our center. Median size of the tumor was 9 cm (SD:6), 73% were high grade, 63% of cases were located on the lower limb (most often on the thigh). 82% had perioperative radiotherapy (72% preoperative). 22% of pts had preoperative chemotherapy. 76% pts underwent R0 resection, the others - R1. 56 pts (22%) had local recurrence and 29 of them had had another radical surgery, most of them extremity amputation (20 pts). 32% pts (79) developed metastases. Median OS was 115 months (95%CI 90.3-NA), while disease free-survival and local recurrence free survival (were 53.5 CI: (39.7 - NA) and not reached, respectively. In a multivariate analysis neoadjuvant radiotherapy was associated with longer LRFS (HR 0.36, 95%CI 0.21-0.65). T3 or T4 tumors and grade 2 or 3 tumors were associated with shorter DFS. Preoperative chemotherapy did not improve DFS (HR 0.82, 95%CI 0.51-1.33). 103 (42%) patient had complications after surgery resulting in prolonged wound healing, 40 of them had more than one complications, 10% patient required hospitalization due to complications, and 8.5% had another surgery for treatment of the complications.
Conclusions
Myxofibrosarcoma is a rare sarcoma subtype, local recurrences after adequate surgery are relatively common and most patient require adjuvant treatment and close follow-up. Treatment should be conducted in experienced sarcoma center with access to multidisciplinary team.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1763P - Initial tumour size and residual mitotic count post-neoadjuvant imatinib linked to shorter relapse-free survival in GIST patients
Presenter: Javier Pozas Perez
Session: Poster session 06
1764P - Role of PIK3CA as a predictive biomarker in metastatic, imatinib-resistant GIST: A ct-DNA substudy of the VOYAGER trial
Presenter: Lennart Schardt
Session: Poster session 06
1765P - Second-line targeted therapy patterns and outcomes of advanced gastrointestinal stromal tumor: A prospective, multicentered real-world study
Presenter: Xinhua Zhang
Session: Poster session 06
1766P - Updated results of the RINGSIDE phase II trial and open-label extension of AL102 for treatment of desmoid tumors
Presenter: Bernd Kasper
Session: Poster session 06
1767P - Pegylated liposomal doxorubicin in symptomatic desmoid tumor
Presenter: Kjetil Boye
Session: Poster session 06
1768P - Desmoid tumors: Experience of a Spanish reference center
Presenter: Ana Gutierrez Ortiz
Session: Poster session 06
1769P - Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior anti–colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
Presenter: Cesar Serrano
Session: Poster session 06
1771P - Blessed: Expanded yccess for DeltaRex-G in vivo gene therapy for sarcoma, pancreas and breast cancer (NCT04091295) and other solid malignancies (IND# 19130)
Presenter: Sant Chawla
Session: Poster session 06
1772P - Phosphoproteomic biomarker for afatinib response stratification in advanced chordoma
Presenter: Christoph Stange
Session: Poster session 06